Evidence map›Paper›PMID 36121618›Full record

ArticleCancer science2022

Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment.

Yudai Kaneko, Kenzo Yamatsugu, Takefumi Yamashita, Kazuki Takahashi, Toshiya Tanaka, Sho Aki, Toshifumi Tatsumi, Takeshi Kawamura, Mai Miura, Masazumi Ishii and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Yudai KanekoResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0967-782X
Kenzo YamatsuguGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Takefumi YamashitaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Kazuki TakahashiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Toshiya TanakaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Sho AkiResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Toshifumi TatsumiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Takeshi KawamuraResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Mai MiuraResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Masazumi IshiiResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Kei OhkuboInstitute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
Tsuyoshi OsawaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Tatsuhiko KodamaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Shumpei IshikawaDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masanobu TsukagoshiSavid Therapeutics Inc., Tokyo, Japan.
Michael ChanslerSavid Therapeutics Inc., Tokyo, Japan.
Akira SugiyamaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4406-9475
Motomu KanaiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Hiroto KatohDepartment of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9440-728X
The University of Tokyo · JPIo Therapeutics (United States) · USTokyo University of Science · JPMedical & Biological Laboratories (Japan) · JPThe University of Osaka · JP

Funding

Japan Society for the Promotion of Science JP21392851Kowa Life Science FoundationProgram for Promoting Researches on the Supercomputer Fugaku hp210172Program for Promoting Researches on the Supercomputer Fugaku JPMXP1020200201Savid Therapeutics, Inc.Takeda Science Foundationthe Japan Agency for Medical Research and Development JP20ck0106414the Japan Agency for Medical Research and Development JP21ak0101096the Japan Agency for Medical Research and Development JP21am0401010
6 · The paper itself

Abstract

Antibody-mimetic drug conjugate is a novel noncovalent conjugate consisting of an antibody-mimetic recognizing a target molecule on the cancer cell surface and low-molecular-weight payloads that kill the cancer cells. In this study, the efficacy of a photo-activating antibody-mimetic drug conjugate targeting HER2-expressing tumors was evaluated in mice, by using the affibody that recognize HER2 (Z

Indexed as

ImmunoconjugatesAnimalsAntibodiesCell Line, TumorErb-b2 Receptor Tyrosine KinasesHumansMiceAntibodiesErb-b2 Receptor Tyrosine KinasesImmunoconjugatesantibody-mimetic drug conjugateHER2pathological complete remissionphotoimmunotherapysilicon phthalocyanine

Identifiers

PMID36121618
PMCPMC9746049
OpenAlexW4296323148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.